ConductScience.org, home
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
API referenceFor AI assistants

Trial · NCT00778817

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 32

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Progression-free Survival Rate at 6 WeeksChemotherapy and Monoclonal Antibody Therapy50percentage of participants
Progression-free Survival Rate at 12 WeeksChemotherapy and Monoclonal Antibody Therapy25percentage of participants
Progression-free Survival Rate at 18 WeeksChemotherapy and Monoclonal Antibody Therapy16.7percentage of participants
Best Response RatesChemotherapy and Monoclonal Antibody TherapyProgressive disease (PD)45percentage of participants
Best Response RatesChemotherapy and Monoclonal Antibody TherapyStable disease (SD)40percentage of participants
Best Response RatesChemotherapy and Monoclonal Antibody TherapyPartial response (PR)5percentage of participants
Best Response RatesChemotherapy and Monoclonal Antibody TherapyComplete response (CR)0percentage of participants
Best Response RatesChemotherapy and Monoclonal Antibody TherapyUnknown response10percentage of participants
Response at 6 WeeksChemotherapy and Monoclonal Antibody TherapyProgressive disease (PD)45percentage of participants
Response at 6 WeeksChemotherapy and Monoclonal Antibody TherapyStable disease (SD)45percentage of participants
Response at 6 WeeksChemotherapy and Monoclonal Antibody TherapyPartial response (PR)0percentage of participants
Response at 6 WeeksChemotherapy and Monoclonal Antibody TherapyComplete response (CR)0percentage of participants
Response at 6 WeeksChemotherapy and Monoclonal Antibody TherapyUnknown response10percentage of participants
Response at 12 WeeksChemotherapy and Monoclonal Antibody TherapyProgressive disease (PD)60percentage of participants
Response at 12 WeeksChemotherapy and Monoclonal Antibody TherapyStable disease (SD)30percentage of participants
Response at 12 WeeksChemotherapy and Monoclonal Antibody TherapyPartial response (PR)0percentage of participants
Response at 12 WeeksChemotherapy and Monoclonal Antibody TherapyComplete response (CR)0percentage of participants
Response at 12 WeeksChemotherapy and Monoclonal Antibody TherapyUnknown response10percentage of participants
Response at 18 WeeksChemotherapy and Monoclonal Antibody TherapyProgressive disease (PD)65percentage of participants
Response at 18 WeeksChemotherapy and Monoclonal Antibody TherapyStable disease (SD)20percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00778817/results

API referenceFor AI assistants